Patents Assigned to BioAlliance C.V.
-
Patent number: 10472422Abstract: Provided herein are tetravalent antibodies that specifically bind to human PSGL-1. Unlike bivalent antibodies, these tetravalent antibodies contain a dimer of two monomers, with each monomer comprising two light chain variable (VL) domains and two heavy chain variable (VH) domains. This format allows for cross-linker/FcR-expressing cell-independent tetravalent antibodies against PSGL-1 that show enhanced efficacy as compared to bivalent PSGL-1 antibodies. These tetravalent antibodies can be used in a variety of diagnostic and therapeutic methods, including without limitation treating T-cell mediated inflammatory diseases, transplantations, and transfusions.Type: GrantFiled: January 6, 2017Date of Patent: November 12, 2019Assignees: ABGENOMICS INTERNATIONAL INC., BIOALLIANCE C.V.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Ying Tsai
-
Patent number: 9950077Abstract: The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.Type: GrantFiled: June 19, 2015Date of Patent: April 24, 2018Assignees: BIOALLIANCE C.V., ABGENOMICS INTERNATIONAL INC.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang, Shu-Hua Lee, Yu-Ying Tsai, Feng-Lin Chiang, Li-An Hu
-
Patent number: 9943610Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: GrantFiled: December 20, 2013Date of Patent: April 17, 2018Assignees: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang
-
Patent number: 9408923Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: GrantFiled: June 17, 2015Date of Patent: August 9, 2016Assignees: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang
-
Patent number: 9334329Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: September 24, 2013Date of Patent: May 10, 2016Assignee: BioAlliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Publication number: 20150352222Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: ApplicationFiled: December 20, 2013Publication date: December 10, 2015Applicants: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa LIN, Shih-Yao LIN, Yu-Chi HSIEH, Chiu-Chen HUANG
-
Patent number: 9193794Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: January 20, 2010Date of Patent: November 24, 2015Assignee: BioAlliance C.V.Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
-
Patent number: 9089614Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: GrantFiled: December 20, 2013Date of Patent: July 28, 2015Assignees: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang
-
Publication number: 20140193437Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicants: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa LIN, Shih-Yao LIN, Yu-Chi HSIEH, Chiu-Chen HUANG
-
Publication number: 20140105899Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: ApplicationFiled: September 24, 2013Publication date: April 17, 2014Applicant: BioAlliance C.V.Inventors: Shih-Yao LIN, Leewen LIN, Yu-Ying TSAI
-
Patent number: 8568718Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: June 8, 2011Date of Patent: October 29, 2013Assignee: Bioalliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Publication number: 20130177579Abstract: The present disclosure relates to antibodies that recognize a carbohydrate on transferrin receptor expressed by nonhematopoietic tumor or cancer cells and uses thereof.Type: ApplicationFiled: January 4, 2013Publication date: July 11, 2013Applicant: BIOALLIANCE C.V.Inventor: BIOALLIANCE C.V.
-
Publication number: 20110280888Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: ApplicationFiled: June 8, 2011Publication date: November 17, 2011Applicant: BioAlliance C.V.Inventors: Shih-Yao LIN, Leewen LIN, Yu-Ying TSAI
-
Patent number: 7982017Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: December 18, 2008Date of Patent: July 19, 2011Assignee: BioAlliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Patent number: 7674605Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: June 7, 2007Date of Patent: March 9, 2010Assignee: BioAlliance C.V.Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee